The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein
about
Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika VirusVirus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesMEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virusStructure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeA high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopesThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseSystematic Bioinformatic Approach for Prediction of Linear B-Cell Epitopes on Dengue E and prM ProteinDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityProtective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus InfectionDengue: knowledge gaps, unmet needs, and research prioritiesA single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesisRecombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop.Delineating antibody recognition against Zika virus during natural infectionA highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteinsDengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive AntibodiesIsolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization.Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis.Vaccines licensed and in clinical trials for the prevention of dengue.Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacyComplexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.Dengue Virus Glycosylation: What Do We Know?Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.Structural Basis of Zika Virus-Specific Antibody Protection.Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies.Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections.Antibody therapies for the prevention and treatment of viral infections.A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
P2860
Q26247258-8740ED54-A2DA-4712-956A-22C05A9F0870Q26314715-1221EEFD-6659-4275-80F9-9DEEB8A19992Q26700001-2CE30D1A-1601-4D27-94AE-26597E8A7927Q26700120-8A4C4D96-3417-4163-B1E4-101AA4E9D245Q26860116-A600556A-BCF0-42DB-9765-EB702AA352F8Q26995782-BF17E5C6-CE77-49AB-9B5A-A8F025F24119Q27468788-A2C7B131-3EFA-432A-821E-961BC409EBABQ27654848-E5C53F6C-6B4C-4D33-A2B7-03B13320949CQ28119679-7E7D09F7-4908-449E-B459-93D64E2115A1Q28729764-AF8984E3-218F-41CA-8B3D-B14A59E6CEA0Q28804076-34EDE42E-FBD2-403B-9CB3-BEB5F79669CBQ30395028-BED9ABA1-084F-4FC6-93E2-6AB9ECC70FD4Q33425879-E506EA4D-32F1-4A1F-A68E-0A9AD111EB15Q33638496-646A1D3A-C93C-4EF9-98CA-A486B27CFC13Q33798068-C1136824-B588-45ED-8226-7FE527B841C2Q35138111-B9693DB1-3FF9-469F-B2D3-2367C072FB2AQ35294150-2625B7D2-7935-4817-B93C-FFAFC3624989Q35654743-F3B6BB74-A5F5-4E1B-8930-6C5E6A243A8CQ35758626-F4A25E2E-FA45-4019-B1E1-D42D43241D38Q35850197-3433AD51-C56E-4854-8F94-66AD8541AEC7Q36205859-08B961D2-92EA-44A2-AB64-594DF38A3A13Q36434210-F49CA218-0A7F-40FD-9EA0-07FC4EF11990Q36597801-D812E3AF-7E65-4798-88F7-483CACF98442Q36878970-169AAF06-CA4D-4541-975F-8CD965913DF0Q37012203-E3C1B451-BB49-4202-B386-6478F5E7A72FQ38994574-7BCBBD1E-E862-4E4F-8330-BBC7E30EA401Q39172722-FC640F2B-CD67-4740-8476-A5BFD3CDF745Q39375868-447393CF-40C0-487E-81EF-FA7FD959F63EQ39535403-CA78D722-AB1B-4ACB-8084-176BC735D54FQ40040450-B650F2EF-E216-4886-A934-551A1E98DAE8Q40044088-291F6E5A-5BF6-442F-981A-76C6156C6170Q40045875-AFB50A72-D359-4345-B10A-8CBAAE6613CCQ40047887-9395FB35-1880-4A5A-9224-FA4415B5E715Q40056291-8D08E23B-0AF5-4B61-AD8D-E12FA7A5ADFDQ40136145-A3CBFF6F-FD95-45F4-A6DA-FCF4C7587C5FQ41676281-D9B90F3E-3E2A-47A7-9446-11DCFBF94467Q42985743-E16EF03B-6081-4A14-9B5D-AD1659BFBA27Q46261471-DAEBABF2-9FD6-465E-BE6F-0AFCD8CB481CQ47143843-688C0681-FBDA-4CA6-BAA9-7F9185A2583BQ47194469-D1A4FE7E-ACED-4A14-B8F5-3FB5119F2903
P2860
The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The potent and broadly neutral ...... ain II of the envelope protein
@ast
The potent and broadly neutral ...... ain II of the envelope protein
@en
The potent and broadly neutral ...... ain II of the envelope protein
@nl
type
label
The potent and broadly neutral ...... ain II of the envelope protein
@ast
The potent and broadly neutral ...... ain II of the envelope protein
@en
The potent and broadly neutral ...... ain II of the envelope protein
@nl
prefLabel
The potent and broadly neutral ...... ain II of the envelope protein
@ast
The potent and broadly neutral ...... ain II of the envelope protein
@en
The potent and broadly neutral ...... ain II of the envelope protein
@nl
P2093
P2860
P50
P356
P1433
P1476
The potent and broadly neutral ...... ain II of the envelope protein
@en
P2093
A Ruklanthi de Alwis
Benjamin J Doranz
Jennifer M Pfaff
Kristen M Kahle
Kristie D Ibarra
Nurgun Kose
S Kyle Austin
Scott A Smith
Xiaoxiao Xiang
P2860
P304
P356
10.1128/MBIO.00873-13
P577
2013-11-19T00:00:00Z